• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
Investigational Drugs
Investigational Drugs

... Cosmetic Act or to the licensing provisions of the Public Health Service Act (58 Stat. 632, as amended (42 U.S.C. 201 et seq.)” (21 CFR 312.2a). However, the following are exemptions to the requirements for an IND as found in 21 CFR ...
Antiplatelet Drugs : Is There a Surgical Risk?
Antiplatelet Drugs : Is There a Surgical Risk?

... ASA is still the only nonsteroidal anti-inflammatory drug (NSAID) used in the treatment and prevention of thromboembolic diseases.15 ASA acts by irreversibly inactivating (for the life of the platelet) the enzyme cyclooxygenase (COX). This enzyme is responsible for the formation of prostaglandins an ...
drugs, biologics, devices - University of Pennsylvania
drugs, biologics, devices - University of Pennsylvania

... Protocol # ...
Microsponge Delivery System: An updated review, current status
Microsponge Delivery System: An updated review, current status

... of controlled and site-specific drug delivery and hence, has attracted wide attention of researchers. This article presents a broad review of Microsponges delivery system discussing the principles and preparation methods. Appropriate analytical techniques for characterization of Microsponges like Pa ...
DRUG ABSORPTION, DISTRIBUTION AND ELIMINATION
DRUG ABSORPTION, DISTRIBUTION AND ELIMINATION

... which are polar and fully ionized at physiologic pH. Most drugs do not fit these criteria, but rather are fairly large, unionized or partially ionized, lipophilic molecules. The general goal of drug metabolism is to transform such compounds into more polar (i.e., more readily excretable) water solub ...
Pharmacology
Pharmacology

... A particular drug might be good for more than one thing, but the drug company has to choose for which use they want to seek approval. • If the drug is ultimately approved, the approval will be for that indication only. • Later, the FDA may approve the drug to treat a different indication after condu ...
IN VITRO Research Article SAKTHIVEL M*
IN VITRO Research Article SAKTHIVEL M*

... and storage. Surfactant forming niosomes are biodegradable, nonimmunogenic and biocompatible6. ...
Sustained release micropellets of paracetamol followed zero
Sustained release micropellets of paracetamol followed zero

... maintaining a constant drug level for a specific period of time with minimum side effects. Sustained release tablets and capsules are commonly taken once or twice daily, compared with counterpart conventional forms that may have to be taken 3 or 4 times daily to achieve the same therapeutic effect. ...
Open Access Could Transform Drug Discovery
Open Access Could Transform Drug Discovery

... mechanism of action for treatment efficacy.[27,28] Beyond the science, however, there are factors that relate to the current precompetitive model for drug discovery in the pharmaceutical industry, which conducts unreported research behind closed doors engendering secrecy while molecular structures a ...
Drug target for lymphatic filariasis
Drug target for lymphatic filariasis

... these two drugs for LF is very effective. These combinations produced prolonged suppression of microfilaraemia (mf) than either drug alone9–11. These drugs are able to kill the parasitic worms available in the blood, but are not completely effective against the adult worms. Moreover, recent studies ...
vL Newron Valuation Report 21JUN16 (with disclaimer)
vL Newron Valuation Report 21JUN16 (with disclaimer)

... 1) The company's expertise in ion channel research, an important class of CNS drugs (e.g. Xadago, evenamide) 2) A development agreement signed with Merck KGaA in 2011 (sarizotan) Strategy to develop CNS drugs to optimal value and then out-license and orphan drugs to commercialization Newron's strate ...
Review of Antibody-Drug Conjugates, Methods in Molecular Biology
Review of Antibody-Drug Conjugates, Methods in Molecular Biology

... chain and the substrate. This procedure requires enzymatic removal of N-linked glycans from the antibody and yields a defined substrate/antibody ratio of 2:1. Alternatively, a mutant aglycosylated IgG1 variant may be generated by site-directed mutagenesis. Interestingly, the mutation introduces an a ...
FDA
FDA

... • Gives FDA new expedited drug development tool – “breakthrough therapy designation” – for assisting sponsors in expediting the development and review of new drugs with preliminary clinical evidence that indicates the drug may offer a substantial improvement over available therapies for patients wit ...
PDF (Injection of synthetic cathinones)
PDF (Injection of synthetic cathinones)

... and the limited number of countries that have included either mephedrone or other synthetic cathinones in recent general population surveys (1) indicate a last year prevalence rate of 1 % or less among adults. However, there are other groups where higher prevalence levels of synthetic cathinone use ...
Importance of in -vitro in -vivo studies in pharmaceutical
Importance of in -vitro in -vivo studies in pharmaceutical

... • Adequate Washout period (> 5 time’s drug half-life). • Administration of food and beverages during study, Recording of adverse events Studies should be carried out in accordance with provisions of guidelines on Good Clinical Practice, Good Manufacturing Practice, and Good Laboratory Practice. In g ...
Prescription Must contain all of the following Except : name of
Prescription Must contain all of the following Except : name of

... c- Elixir is a solution that contains alcohol as diluent. d- Regular tablet is a solid dosage form. 114- The duration for treatment of Brucellosis is: a- 2 weeks b- 2 months c- 6 weeks* d- 6 months 115- SNF is: a- Southern Non-fatal Fever b- Sinusitis Nasal Formula c- Saudi National Formulary* d- Co ...
Development of Tamper Deterrent Formulations
Development of Tamper Deterrent Formulations

... implementing their own REMS. While it is still not clear how TDF could serve as part of any proposed REMS, the new regulatory requirement had brought attention to the importance of TDF. It is also interesting to note that some researchers have called for future generic product of abuse deterrent bra ...
rencana program dan kegiatan pembelajaran
rencana program dan kegiatan pembelajaran

... costs associated with drug use. DTCs can provide the leadership and structure to select appropriate drugs for the formulary, identify drug use problems, promote rational drug use, and help reduce drug costs to acceptable levels. A health care organization’s Drug and Therapeutics Committee has numero ...
FDA Supplement - Oregon State University Research Office
FDA Supplement - Oregon State University Research Office

... may only be waived in certain emergency situations. Waiver of Documentation of Informed consent: If you are seeking a waiver of documentation (signature) of informed consent, justify the request here. Only research activities that are minimal risk and do not require a signature outside the research ...
DEVELOPMENT AND OPTIMIZATION OF PRONIOSOMES FOR ORAL DELIVERY OF GLIPIZIDE
DEVELOPMENT AND OPTIMIZATION OF PRONIOSOMES FOR ORAL DELIVERY OF GLIPIZIDE

... drug carrier “Proniosomes”. Proniosomes is a dry formulation using suitable carrier coated with non-ionic surfactants and can be converted into niosomes immediately before use by hydration.These proniosome-derived niosomes are as good as or even better than conventional niosomes.Glipizide loaded Sor ...
ORODENTAL DELIVERY SYSTEMS: AN OVERVIEW Review Article  NEHA M. MUNOT
ORODENTAL DELIVERY SYSTEMS: AN OVERVIEW Review Article NEHA M. MUNOT

... Dental diseases are a major health problem in all parts of the world, common in all age groups, races and genders. The percentage of dental diseases has grown to a large extent in recent years. Around 70% of population suffers from dental problems. The human population is affected by major of oral d ...
United States Court of Appeals Argued March 1, 2007 No. 04-5350
United States Court of Appeals Argued March 1, 2007 No. 04-5350

... § 312.34(b)(3). Sponsors may not profit from any approved treatment IND program and may only “recover costs of manufacture, research, development, and handling of the investigational drug.” Id. § 312.7(d)(3).4 ...
3-Hydroxy-N-Methylpyrrolidone and Use as
3-Hydroxy-N-Methylpyrrolidone and Use as

... tion products of castor oil and ethylene oxide combin 0 ing about 30 to about 35 moles of ethylene oxide per mole of castor oil; liquid glyceryl triester of a lower methylpyrrolidone provides at least equal and often superior enhancement of transdermal absorption while molecular weight fatty acid; l ...
Cengage Learning
Cengage Learning

... increases GI secretions, and relaxes sphincters – Cholinergic drugs simulate these actions – Anticholinergic drugs inhibit these actions ...
Identification of novel therapeutics for complex diseases from
Identification of novel therapeutics for complex diseases from

... and multifactorial [6]; and frequently arise as a consequence of interaction between genes and the environment. Recently, GWAS have begun to unravel the complicated genetic basis of complex diseases. Sheer statistical power has allowed GWAS to successfully identify some associations between Single N ...
< 1 ... 34 35 36 37 38 39 40 41 42 ... 161 >

Orphan drug

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as extended exclusivity periods, all intended to encourage the development of drugs which might otherwise lack a sufficient profit motive. The assignment of orphan status to a disease and to any drugs developed to treat it is a matter of public policy in many countries, and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development.According to Thomson Reuters in their 2012 publication ""The Economic Power of Orphan Drugs"", there has been increased investing in orphan drug Research and Development partly due to the U. S. Orphan Drug Act (ODA) 1983 and similar Acts in other regions of the world and also driven by ""high-profile philanthropic funding."" The period between 2001 to 2011 was the ""most productive period in the history of orphan drug development, in terms of average annual orphan drug designations and orphan drug approvals."" For the same decade the compound annual growth rate (CAGR) of the orphan drugs was an ""impressive 25.8 percent, compared to only 20.1 percent for a matched control group of non-orphan drugs."" By 2012 the market for orphan drugs was worth USD$637 million compared to the USD$638 million matched control group of non-orphan drugs, Thomson Reuters.By 2012, ""the revenue-generating potential of orphan drugs [was] as great as for non-orphan drugs, even though patient populations for rare diseases are significantly smaller. Moreover, we suggest that orphan drugs have greater profitability when considered in the full context of developmental drivers including government financial incentives, smaller clinical trial sizes, shorter clinical trial times and higher rates of regulatory success.""
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report